Pre-Translational Approaches to the Conquest of Immune Disorders by Targeting Fcγ Receptors
Pre-Translational Approaches to the Conquest of Immune Disorders by Targeting Fcγ Receptors
批准号:
17209017
负责人:
TAKAI Toshiyuki
金额:
$19.55万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (A)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2007
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Fc receptors play pivotal roles in immune regulation, and their dysregulation leads to immune-related diseases including allergic inflammationand aud autoimmunity. We have obtained in this project the following accomplishments:1) Establishment of the importance of inhibitory Fcγ receeptor, FcγRIIB, in immune regulation and autoimmune dieseases, such as autoimmune glomerulonephritis.2) Establishment of animal models for immune disorders by the use of Feγ receptor gene-targeted mice.3) Establishment of immune cells with the immortalized growth and immune functions by the use of SV40LT-transgenic mice.Among these, in particular, we have identified the pivotal roles of activating-type Fcγ receptors, but not inhibitory FcγRIB, in the development of autoimmune diabetes of NOD mice. Type 1 diabetes mellitus (T1D) in humans is an organ-specific autoimmune disease in which pancreatic islet β cell are ruptured by autoreactive T cells. NOD mice, the most commonly used animal model of T1D, show ea … More rly infiltration of leukocytes in the islets (insulitis), resulting in islet destruction and diabetes later. NOD mice produce various islet β cell-specific autoantibodies, although it remains a subject of debate regarding whether these autoantibodies contribute to the development of T1D or not. To investigate the possible role of FcγRs in NOD mice, we have generated several FcγR-less NOD lines, namely FcR common γ chain (FcRγ)-deficient ((NOD.γ^<-/->), FcγRIII-deficient (NOD.III^<-/->), FcγRIIB-deficient (NOD.IIB^<-/->), and both FcRγ and Fcγ and FcγRIIB-deficient NOD (NOD.null) mice. We have shown significant protection from diabetes in NOD.γ^<-/->, NOD.III^<-/->, and NOD.null but not in NOD.IIB^<-/-> mice even with grossly comparable production of autoantibodies among them. Insulitis in NOD.γ^<-/-> mice was also alleviated. Adoptive transfer of bone marrow-derived dendritic cells or NK cells from NOD mice rendered NOD.γ^<-/-> animals more susceptible to diabetes, suggesting a possible scenario in which activating FcγRIII on NK cells trigger antibody-dependent effector functions and inflammation. These findings highlight the critical roles of activating FcγRs in the development of T1D, and indicate that FcγRs are novel targets for therapies for T1D. Less
期刊论文(70)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Vav1 controls DAP10-mediated natural eytotoxicity by regulating actin and microtubule dynamics.
Vav1 通过调节肌动蛋白和微管动力学来控制 DAP10 介导的天然细胞毒性。
DOI:
--
发表时间:
2006
期刊:
J. Immunol 177(4)
影响因子:
--
作者:
[Graham DB , et. al.]
通讯作者:
et. al.
DOI:
10.1128/iai.01493-07
发表时间:
2008-04-01
期刊:
INFECTION AND IMMUNITY
影响因子:
3.1
作者:
[Masuda, Atsuhiro, Yoshida, Masaru, Azuma, Takeshi]
通讯作者:
Azuma, Takeshi
Plexin-Al and its interaction with DAP12 in immune responses and bone homeostasis.
Plexin-Al 及其与 DAP12 在免疫反应和骨稳态中的相互作用。
DOI:
--
发表时间:
2006
期刊:
Nat. Cell Biol 8(6)
影响因子:
--
作者:
[Takegahara N , et. al.]
通讯作者:
et. al.
Hydronephrosis associated with anti-urothelial and anti-nuclear autoantibodies inBALB/c-Fcgr2b^<-/->lPdcdlh^<-/-> mice
BALB/c-Fcgr2b^<-/->lPdcdlh^</-/-> 小鼠中与抗尿路上皮和抗核自身抗体相关的肾积水
DOI:
--
发表时间:
2005
期刊:
J. Exp. Med 202
影响因子:
--
作者:
[Okazaki T, et. al.]
通讯作者:
et. al.
A CD200 receptor-like protein CD200R3 functions. as an activating rece ptor expressed exclusively on basophils and mast cells
CD200 受体样蛋白 CD200R3 发挥作用。
DOI:
--
发表时间:
2007
期刊:
J. Immunol 179
影响因子:
--
作者:
[Kojima T, et. al.]
通讯作者:
et. al.
共 48 条
Mechanism of LILRB4-mediated immune checkpoint
-
批准号:19H03484
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.15万
-
财政年份:2019
-
负责人:TAKAI Toshiyuki
-
依托单位:
Modulating immunological memory of antibody-producing cells
-
批准号:17K19539
-
项目类别:Grant-in-Aid for Challenging Research (Exploratory)
-
资助金额:$4.16万
-
财政年份:2017
-
负责人:TAKAI Toshiyuki
-
依托单位:
Identification of molecular characteristics of pathogenic autoantibody-producing cells
-
批准号:16H05201
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.15万
-
财政年份:2016
-
负责人:TAKAI Toshiyuki
-
依托单位:
Platelets convert peripheral blood circulating monocytes to regulatory cells via immunoglobulin G and activating-type Fcg receptors.
-
批准号:26670230
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.41万
-
财政年份:2014
-
负责人:TAKAI Toshiyuki
-
依托单位:
Novel immune regulation by PirB-related multiple ligands
-
批准号:24249016
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$29.45万
-
财政年份:2012
-
负责人:TAKAI Toshiyuki
-
依托单位:
Studies on the origin of high-photosynthesis in rice high-yielding cultivar, Takanari, based on its pedigree analysis
-
批准号:22780017
-
项目类别:Grant-in-Aid for Young Scientists (B)
-
资助金额:$2.25万
-
财政年份:2010
-
负责人:TAKAI Toshiyuki
-
依托单位:
Prediction of immune disorders by evaluation of serum IgG reactivity to random peptide library
-
批准号:22659057
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$1.93万
-
财政年份:2010
-
负责人:TAKAI Toshiyuki
-
依托单位:
Molecular Basis for the Immune Regulatory Receptor System
-
批准号:20249026
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$20.63万
-
财政年份:2008
-
负责人:TAKAI Toshiyuki
-
依托单位:
IMMUNE REGULATION BY IMMUNOGLOBULIN-LIKE RECEPTORS
-
批准号:14207014
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$19.05万
-
财政年份:2002
-
负责人:TAKAI Toshiyuki
-
依托单位:
Development of Autoimmune Disease Models Based on FcyRIIB-Deficient Mice
-
批准号:12557014
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$7.55万
-
财政年份:2000
-
负责人:TAKAI Toshiyuki
-
依托单位:
Analysis of Physiological Roles of Novel Immunoglobulin-Like Receptors, PIR
-
批准号:11470031
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$4.35万
-
财政年份:1999
-
负责人:TAKAI Toshiyuki
-
依托单位:
ANALYSIS OF IGA NETWORK BY GENE TARGETING
-
批准号:08670149
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.47万
-
财政年份:1996
-
负责人:TAKAI Toshiyuki
-
依托单位:
海外基金